Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome

Figures

• 

  Figure 1.. Risk of peripheral artery disease and venous thromboembolism events in the placebo group by baseline lipoprotein(a) or LDL-Ccorrected quartiles. Peripheral artery disease (PAD) events (top) and venous thromboembolism (VTE) events (bottom) in the placebo group are shown according to baseline quartile of lipoprotein(a) (Lp(a); left) or baseline quartile of corrected low-density lipoprotein cholesterol (LDL-Ccorrected; right). The hazard ratios (HRs [95% CIs]) for quartile 2, quartile 3, and quartile 4, relative to quartile 1, are 1.40 (0.83–2.35), 1.35 (0.81–2.28), and 2.22 (1.38–3.57) for lipoprotein(a) and PAD events; 1.06 (0.48–2.37), 1.03 (0.46–2.30), and 1.64 (0.80–3.38) for lipoprotein(a) and VTE events; 1.03 (0.62–1.70), 1.34 (0.84–2.15), and 1.46 (0.91–2.32) for LDL-Ccorrected and PAD events; and 0.72 (0.33–1.58), 0.90 (0.43–1.86), and 1.00 (0.49–2.05) for LDL-Ccorrected and VTE events. P values reflect linear trend across quartiles in an unadjusted Cox regression model.

• 

  Figure 2.. Effects of alirocumab or placebo on peripheral artery disease and venous thromboembolism events. Kaplan-Meier curves depict the cumulative rate of peripheral artery disease (PAD) events (blue), venous thromboembolism (VTE) events (red), and the combination of PAD or VTE events (green). HR indicates hazard ratio.

• 

  Figure 3.. Treatment effect of alirocumab on peripheral artery disease and venous thromboembolism events according to baseline quartile of LDL-Ccorrected or lipoprotein(a). Hazard ratios (HRs; alirocumab:placebo) for peripheral artery disease (PAD) events (top) and venous thromboembolism (VTE) events (bottom) according to baseline quartile of lipoprotein(a) (left) or baseline quartile of corrected low-density lipoprotein cholesterol (LDL-Ccorrected; right). Overall treatment effect is shown in red. P values indicate test of linear trend across baseline quartiles.